Eam Investors, LLC Apellis Pharmaceuticals, Inc. Transaction History

Eam Investors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$76.68 - $93.31 $1.95 Million - $2.37 Million	25,407 New	25,407 $2.31 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $1.22 Million - $1.91 Million	27,355 New	27,355 $1.87 Million
Q3 2021 Nov 12, 2021	SELL	$31.4 - $69.84 $1.12 Million - $2.5 Million	-35,746 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $1.46 Million - $2.32 Million	35,746 New	35,746 $2.26 Million
Q1 2021 May 11, 2021	SELL	$40.8 - $57.39 $1.5 Million - $2.1 Million	-36,677 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$30.79 - $57.2 $1.13 Million - $2.1 Million	36,677 New	36,677 $2.1 Million

302

112M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.19B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.